Table 1 Baseline demographic and IVF characteristics and outcomes of the patients undergoing ovarian stimulation cycle for fertility preservation. One IVF cycle for each patient.

From: Patients with gynecological malignancies are similar to other IVF patients without cancer for clinical and molecular reproductive parameters and DNA damage response pattern

 

Control IVF patients

IVF patients with gynecological malignancies

p

n

31

39

 

Female age (y)

34.0 ± 3.7 (29–39)

35.2 ± 2.9 (29–39)

0.164

BMI (kg/m2)

21.7 ± 2.1 (18.3–26.0)

23.5 ± 1.8 (20.3–27.5)

0.001

AMH

1.9 ± 0.6 (0.9–3.3)

1.9 ± 0.7 (0.7–3.2)

0.864

Duration of stimulation

10.3 ± 1.1 (8–12)

10.8 ± 2.1 (7–16)

0.198

Daily dose of GN (IU)

343.5 ± 88.3 (225–450)

352.0 ± 90.5 (225–450)

0.796

Peak E2 (pg/mL)

1942.7 ± 709.5 (560–3148)

1456.3 ± 561.0 (587–2996)

0.002

Total number of oocytes

12.2 ± 5.5 (4–22)

10.0 ± 4.6 (3–20)

0.077

MII oocytes

9.3 ± 4.9 (3–19)

8.0 ± 3.9 (3–17)

0.229

MII oocyte/total oocyte ratio (%)

75.4 ± 16.4 (50–100)

81.2 ± 14.0 (50–100)

0.127

Fertilization rate after ICSI (%)*

81.3 ± 8.3 (69.2–94.7)

82.0 ± 17.4 (37.5–100)

0.906

Day 5 blastulation rate (%)*

45.7 ± 19.4 (13.3–83.3)

47.1 ± 12.9 (23.1–66.7)

0.833

  1. IVF characteristics and outcomes of the patients undergoing ovarian stimulation cycle for fertility preservation. One IVF cycle for each patient.
  2. Data are mean ± SD (range).
  3. p values by t-test.
  4. *14 women in the control group, 12 women in the gynecological cancer group had embryo cryopreservation.
  5. BMI body mass index, AMH anti-Mullerian hormone, GN gonadotropin, E2 estradiol, MII metaphase-II.
Back to article page